Lumito publishes investor letter
Lumito AB (publ) (”Lumito” or the ”Company”) today publishes an investor letter where the Company, among other things, follows up on the objectives that were announced in connection with the rights issue during the summer.
”We have taken clear steps forward in the commercialisation of SCIZYS. Through more qualified customer and partner discussions, progress in our pilot projects, and a strengthened presence at key international industry platforms, we have broadened our pipeline and created more concrete routes to market. Going forward, our focus is to continue translating the growing interest in SCIZYS into pilot projects, partnerships, and long-term commercial collaborations”, says Sanna Wallenborg, CEO of Lumito.
The investor letter is attached and is also available to read on Lumito’s website: https://lumito.se/wp-content/uploads/2026/10/261004_5-Lumito-nyhetsbrev-oktober-2026-ENG.pdf
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/
The share is traded on NGM Growth Market under the name LUMITO, and Mentor is Mangold Fondkommission.